BioSkryb provides an integrated single‑cell multiomics platform that simultaneously amplifies and sequences the whole genome, full‑length transcriptome, and surface proteins from individual cells in a single‑day, automation‑compatible workflow. Its patented primary template‑directed amplification achieves >97% genome coverage and femtogram‑scale sensitivity, enabling high‑resolution genotype‑to‑phenotype data from low‑input or archival samples. The platform includes the ResolveOME kit and BaseJumper bioinformatics tools to deliver clinical‑grade, AI‑ready datasets for research, drug development, and diagnostic applications.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional bulk sequencing masks cellular heterogeneity, and existing single-cell methods often suffer from low genome coverage, high allelic dropout, and fragmented DNA/RNA workflows, limiting the ability to link genotype to phenotype in rare cells or low-input samples.
Solution
BioSkryb Genomics provides an integrated single-cell multiomics platform that simultaneously amplifies and sequences the whole genome, full-length transcriptome, and surface proteins from individual cells in a single-day, automation‑compatible workflow. Their patented primary template‑directed amplification (PTA) achieves >97% genome coverage with uniformity, while also delivering superior full‑length RNA capture. The ResolveOME kit combines PTA‑based whole‑genome amplification with reverse transcription in the same tube, eliminating sample splitting and reducing hands‑on time. Data are processed through the BaseJumper bioinformatics platform, which offers automated quality control, variant calling, and visualization tools, enabling researchers to generate clinical‑grade, AI‑ready datasets from ultra‑low input or archival samples.
Target Audience
Primary customers are academic and industry researchers in genomics, oncology, neurology, and drug development who require high‑resolution single‑cell genotype‑to‑phenotype data, as well as biopharma teams developing diagnostics and AI‑driven biomarker pipelines.
Features
- PTA‑based whole‑genome amplification delivering >97% coverage and low allelic dropout for single cells and low‑input DNA (4 pg–10 ng)
- Integrated workflow that generates both whole‑genome and full‑length transcriptome libraries from the same cell without intermediate cleanup
- Compatibility with various single‑cell isolation methods, sequencing platforms, and downstream applications (WGS, exome, targeted panels)
- Scalable kit format supporting up to 96 reactions per batch for high‑throughput experiments
- BaseJumper cloud and local bioinformatics platforms providing automated QC, variant analysis, and visualization for multiomic data
- Femtogram‑scale sensitivity enabling analysis of quantity‑not‑sufficient (QNS) samples, fine‑needle aspirates, and FFPE tissue
- Complete starter packs including reagents, consumables, and hardware for streamlined laboratory implementation